
1 - 10 employees
🏥 Healthcare
🧬 Biotechnology
💊 Pharmaceuticals
💰 $75.5M Series A - Actithera on 2025-07
Healthcare • Biotechnology • Pharmaceuticals
Actithera is a biotechnology company developing next-generation radioligand therapies (RLTs) for cancer. The company designs molecules that link radioactive isotopes to small molecules and modified peptides to deliver targeted, sustained radiation to tumors while sparing healthy tissues. Actithera is a discovery-stage firm with assets in IND-enabling studies and aims to enable effective, better-tolerated, personalized cancer treatments with fewer therapy cycles through proprietary chemistry that matches radionuclide half-lives to tumor residence time.
Selected: 🆕 Date Added.
🕒 August 6
Global Regulatory Head directing Actithera’s radiopharmaceutical RLT regulatory strategy and submissions. Leading health authority interactions, compliance, and oncology approval planning.
🍂 Massachusetts – Remote
💵 $150k - $275k / year
💰 $75.5M Series A - Actithera on 2025-07
⏰ Full Time
🔴 Lead
🚔 Compliance
👻 Ghost score 6%